Yumanity Therapeutics (FRA:8IY) Long-Term Capital Lease Obligation : €0.00 Mil (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Long-Term Capital Lease Obligation?

Yumanity Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2022 was €0.00 Mil.

Yumanity Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Mar. 2022 (€8.27 Mil) to Jun. 2022 (€0.00 Mil) but then stayed the same from Jun. 2022 (€0.00 Mil) to Sep. 2022 (€0.00 Mil).

Yumanity Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2019 (€0.10 Mil) to Dec. 2020 (€11.94 Mil) but then declined from Dec. 2020 (€11.94 Mil) to Dec. 2021 (€8.33 Mil).

Yumanity Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Yumanity Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Long-Term Capital Lease Obligation Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Long-Term Capital Lease Obligation

0.10

11.94

8.33

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial							9.14	8.33	8.27	-	-

Yumanity Therapeutics (FRA:8IY) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Yumanity Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (FRA:8IY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines